Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Human IgG1 (N297A) kappa

Human IgG1 (N297A) kappa, Isotype Control

Humanized

Atezolizumab (0, 2.5, 5, 10, 20, and 40 μg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells^[1].
Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway^[1].
Atezolizumab (10 μg/ml; 24 hours; HOS and 143B cells) induces autophagy in osteosarcoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

• 
  Human IgG1 kappa

• 
  Flow cytometry analysis of PD-L1 overexpression HEK293 cells labelling PD-L1 with Atezolizumab at 67nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

• [1]. Cha E, et al. PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol. 2015 Jun;42(3):484-7.  [Content Brief]

  [2]. Liu Z, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma. Cell Death Dis. 2021;12(2):164. Published 2021 Feb 8.  [Content Brief]